CFDE Data Portal | Search TUBAP13

	Label	Description
	TUBAP13 Gene (Entity type)	ENSG00000242575 - tubulin alpha pseudogene 13
	GSE111247 temozolomide LN-308 14 v 12 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 4 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE199862 Chk1 inhibition 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216540 fulvestrant 10 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE225901 dexamethasone 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 4 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE244730 erlotinib PC-9 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE149768 hypoxanthine 3 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS

TUBAP13

ENSG00000242575 - tubulin alpha pseudogene 13

GSE111247 temozolomide LN-308 14 v 12 human dn

A Gene Set from LINCS

GSE238018 MXRA8 knockout MDA-MB-231 3 v 2 human up

A Gene Set from LINCS

GSE239844 crizotinib 4 v 9 human dn

A Gene Set from LINCS

GSE199862 Chk1 inhibition 3 v 1 human dn

A Gene Set from LINCS

GSE216540 fulvestrant 10 v 6 human dn

A Gene Set from LINCS

GSE225901 dexamethasone 0 v 1 human up

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 4 v 5 human up

A Gene Set from LINCS

GSE244730 erlotinib PC-9 0 v 1 human up

A Gene Set from LINCS

GSE149768 hypoxanthine 3 v 4 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.